CRL 5861 (PURIFIED POLOXAMER 188) IN SICKLE CELL DISEASE & VASO OCCLUSIVE CRISIS

CRL 5861（纯化的泊洛沙姆 188）治疗镰状细胞病

• 批准号: 6302992
• 负责人: BRIAN K ADLER
• 金额: $ 2.95万
• 依托单位: UNIVERSITY OF ALABAMA AT BIRMINGHAM
• 依托单位国家: 美国
• 财政年份: 1999
• 资助国家: 美国
• 起止时间: 1999-12-01 至 2000-11-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6302992
• 关键词: blood disorder chemotherapy; blood vessel occlusion; clinical research; ethylene oxide; human subject; human therapy evaluation; pathologic process; sickle cell anemia

This study has closed due to completion of patient accrual nationwide. The results demonstrated a strong trend, without reaching statistical significance, for the drug reducing the duration of a sickle cell crisis. Toxicity from the drug was mild. The study was a randomized, double blind, placebo controlled trial of the use of Flocer for the treatment of sickle cell crisis.

由于完成了全国范围内的患者招募，本研究已关闭。 结果表明，该药物具有缩短镰状细胞危象持续时间的强烈趋势，但未达到统计学显著性。药物毒性轻微。 该研究是一项使用Flocer治疗镰状细胞危象的随机、双盲、安慰剂对照试验。